MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BOLT had $8,152K increase in cash & cash equivalents over the period. -$9,804K in free cash flow.

Cash Flow Overview

Change in Cash
$8,152K
Free Cash flow
-$9,804K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-7,144 -19,601
Depreciation and amortization
290 746
Stock-based compensation expense
407 1,334
Accretion of discount on marketable securities
130 379
Gain on sale of property and equipment
0 288
Non-cash lease expense
636 1,239
Prepaid expenses and other assets
86 236
Accounts payable and accrued expenses
-1,882 -3,351
Operating lease liabilities
-594 -1,026
Deferred revenue
-1,229 -1,533
Other long-term liabilities
0 133
Net cash used in operating activities
-9,732 -22,962
Purchases of property and equipment
72 -
Proceeds from sales of property and equipment
0 963
Purchases of marketable securities
1,719 15,457
Maturities of marketable securities
19,675 39,838
Net cash provided by investing activities
17,884 25,344
Proceeds from issuance of common stock
0 14
Net cash provided by financing activities
0 14
Net increase (decrease) in cash
8,152 2,396
Cash and cash equivalents at beginning of period
8,970 -
Cash and cash equivalents at end of period
19,518 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. (BOLT)